Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis
NCT00257530
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
80
Enrollment
OTHER
Sponsor class
Conditions
Cutaneous Leishmaniasis
Interventions
DRUG:
Imiquimod
Sponsor
Drugs for Neglected Diseases